Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- LVH
Study Overview
Brief Summary
Heart failure causes significant morbidity and mortality and is the most rapidly increasing cardiovascular diagnosis in North America overall prevalence is estimated at 0.4% to 2.4%. Recently, heart failure with a preserved ejection fraction (HFNEF) was found in up to 50% of patients with symptomatic heart failure. Many studies have demonstrated that HFNEF has a poor prognosis with a mortality rate of up to 8% per year and a 50% chance of needing to be admitted to hospital in the next year. There are no proven therapies for this type of heart failure.
Aldosterone blockers (these drugs block a hormone that is elevated in patients with heart failure) are used in other types of heart failure. Our goal is to see if this type of drug improves the function of the heart by looking at the thickness of the heart muscle using MRI. Also we will measure the amount of tissue formation and breakdown in the heart. The trial will be done using both the drug and a placebo so that we can see what effects are due to the drug.
Detailed Description
Aldosterone antagonists have shown efficacy in systolic heart failure and in patients with post-myocardial infarction systolic dysfunction in three major randomized placebo controlled trials. Together these trials have demonstrated a reduction in mortality, hospitalization and a regression in left ventricular mass by MRI.
Primary Objective The primary objective of this study will be to assess the change in markers of collagen turnover and correlate this with specific measures of left ventricular mass regression and diastolic function on MRI after 4 months of aldosterone blockade.
Study Design and Methods This study is a double-blind, concealed allocation, randomized trial at the University of Alberta where patients with diastolic heart failure will be randomized to spironolactone or matching placebo for 4 months. Outcomes assessed include LV mass by MRI, collagen markers, other biomarkers, clinical outcomes, quality of life and exercise testing
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •HF by Framingham criteria
- •At least one admission to hospital for HF within the last 180 days
- •New York Heart Association Class II thru IV
- •Echocardiographic criteria:At least moderate diastolic dysfunction, Ejection fraction >45%
Exclusion Criteria
- •Creatinine clearance <40 mls/min/1.73m2
- •Potassium >5.0 mmol/L
- •Recent acute coronary syndrome in the prior 4 weeks
- •Planned revascularization, defibrillator or pacemaker in next 4 months
- •Known previous intolerance to aldosterone antagonist
Arms & Interventions
1
Spironolactone
Intervention: Spironolactone (Drug)
2
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
LVH
Time Frame: 4 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Justin Ezekowitz
Professor
University of Alberta